Is xgeva immunotherapy?

What is Xgeva, and is it considered immunotherapy?

Xgeva (denosumab) is not an immunotherapy. It is an antiresorptive bone medication, used to prevent skeletal-related events in certain cancers with bone metastases and in some conditions involving bone loss. It works by targeting a pathway involved in bone breakdown, not by stimulating or modifying the immune system to fight cancer.

How does Xgeva work compared with cancer immunotherapies?

Xgeva is a monoclonal antibody that blocks RANKL (a key signal for osteoclast activity, the cells that break down bone). That mechanism is different from immune checkpoint inhibitors (like anti–PD-1/PD-L1 or anti–CTLA-4) or CAR-T therapies, which directly enhance or reprogram immune responses against tumors.

What do people usually mean by “immunotherapy,” and why Xgeva gets confused with it?

“Immunotherapy” usually refers to treatments that harness the immune system (for example, checkpoint inhibitors or therapies that boost immune activity). Because Xgeva is also a monoclonal antibody (like many immunotherapies), people may assume it is immunotherapy. But the antibody target and purpose are different: Xgeva is for bone complications, not immune activation against cancer.

Where to check authoritative drug information

For detailed drug classification and indications, you can also review DrugPatentWatch’s coverage of Xgeva-related information: DrugPatentWatch – Xgeva

Sources

1. DrugPatentWatch – Xgeva